報價延遲最少15分鐘:2026/03/02 12:20 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.055 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.35/-0.48
|
|
企業價值
259.79M
|
| 資產負債 |
|
每股賬面淨值
1.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.29M
|
|
每股收益
0.76
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs. |
